Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ)   SEPTEMBER 2007 , Volume 65 , Number 6; Page(s) 23 To 28.
 
Paper: 

LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONATED HEPARIN IN PATIENTS WITH NON ST-ELEVATION ACUTE CORONARY SYNDROME: A RANDOMAIZED CLINICAL TRIAL

 
 
Author(s):  ZAND PARSA AMIR FARHANG*, JAFARI H., TABATABAEI GH.H.
 
* IMAM KHOMEINI HOSPITAL, KESHAVARZ BLVD., TEHRAN
 
Abstract: 

Background: Despite the overwhelming progress that has been accomplished in the prevention of mortality due to cardiovascular disease, coronary artery disease (CAD) is the leading cause of death in the world.
The aim of this study was to compare of the effects of enoxaparin versus unfractionated heparin (UFH) on major clinical events, including mortality, myocardial infarction (MI), and recurrent angina, as well as bleeding in patients with non ST elevation acute coronary syndrome (NSTEACS). We also studied the need for coronary angiography and revascularization (PCI or CABG) in these patients.
Method: Two-hundred patients were enrolled in this study, 100 of whom received intravenous UFH (an initial bolus of 5000 U followed by continuous infusion of 1000 U/h) and 100 received enoxaparin subcutaneous injections of 1mg/kg twice daily for a minimum of 72 h. During their admission we recorded data regarding death, MI, recurrent angina, need for angiography and revascularization, and major and minor bleeding.
Results: The incidence of recurrent angina, total mortality and the need for revascularization were significantly lower in patients receiving enoxaparin compared to those receiving UFH, at 17% vs. 39% (p=0.002), 0% vs. 3% (p=0.035), 14% vs. 33% (p=0.001), respectively. However, there was no significant difference regarding the incidence of MI, major bleeding and cardiac death between the two groups.
Conclusions: This study showed that, in patients with NSTEACS, enoxaparin was superior to UFH regarding the prevention of major in-hospital clinical events, especially recurrent angina and the need for revascularization. We therefore recommend enoxaparin as an alternative antithrombotic agent to UFH in patients with NSTEACS.

 
Keyword(s): ENOXAPARIN, UNFRACTIONATED HEPARIN, LOW MOLECULAR WEIGHT HEPARIN, NON ST ELEVATION ACUTE CORONARY SYNDROME
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

ZAND PARSA, A., & JAFARI, H., & TABATABAEI, G. (2007). LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONATED HEPARIN IN PATIENTS WITH NON ST-ELEVATION ACUTE CORONARY SYNDROME: A RANDOMAIZED CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), 65(6), 23-28. https://www.sid.ir/en/journal/ViewPaper.aspx?id=104237



Vancouver: Copy

ZAND PARSA AMIR FARHANG, JAFARI H., TABATABAEI GH.H.. LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONATED HEPARIN IN PATIENTS WITH NON ST-ELEVATION ACUTE CORONARY SYNDROME: A RANDOMAIZED CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ). 2007 [cited 2021July28];65(6):23-28. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=104237



IEEE: Copy

ZAND PARSA, A., JAFARI, H., TABATABAEI, G., 2007. LOW MOLECULAR WEIGHT HEPARIN VERSUS UNFRACTIONATED HEPARIN IN PATIENTS WITH NON ST-ELEVATION ACUTE CORONARY SYNDROME: A RANDOMAIZED CLINICAL TRIAL. TEHRAN UNIVERSITY MEDICAL JOURNAL (TUMJ), [online] 65(6), pp.23-28. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=104237.



 
 
Persian Abstract Yearly Visit 47
 
 
Latest on Blog
Enter SID Blog